Sanofi: positive data in lung cancer

(CercleFinance.com) - Sanofi says a last-minute presentation at the ESMO congress showed that monotherapy with Libtayo reduced the risk of death by 32%, compared to chemotherapy, in patients with non-small cell lung cancer.


The health group adds that a pre-specified analysis of data from patients with 50% or more of their tumour cells expressing PD-L1 showed that Libtayo reduced the risk of death by 43%.

These results will form the basis of submissions to regulatory authorities, particularly in the US and the European Union. Libtayo is being jointly developed by Sanofi and Regeneron.


Copyright (c) 2020 CercleFinance.com. All rights reserved.